Abstract：Objective: To observe the correlation between serum CEA, CA125 and cytokeratin 19 fragment (cyfra21-1) levels and the survival of patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the application value of three tumor markers in the prognosis of patients with advanced NSCLC. Methods: The clinical characteristics, short-term efficacy and prognosis of 105 patients with stage III B and IV NSCLC treated in our hospital from January 2015 to June 2018 were retrospectively analyzed. Serum CEA, CA125 and Cyfra21-1 levels were measured before and after treatment. Results:There were significant differences in serum CEA, CA125 and Cyfra21-1 levels between adenocarcinoma and squamous cell carcinoma, stage III B and IV, and the number of extrapulmonary metastasis sites < 3 and < 3 (all P < 0.05). The levels of serum CEA, CA125 and Cyfra21-1 after treatment were significantly different from those before treatment (all P < 0.05); the progression-free survival (PFS) and total survival (OS) of patients with high-level indicators (CEA < 5 ng/ml, CA125 < 15 ng/ml, and Cyfra21-1 < 5 U/ml) were less than those of patients with low-level indicators (CEA < 5 ng/ml, CA125 < 15 ng/ml, Cyfra21-1 < 5 U/ml) (all P < 0.05). 05). Conclusion: Serum CEA, CA125 and Cyfra21-1 levels have high clinical value in judging the short-term therapeutic effect and prognosis of patients with advanced NSCLC.
李雪芹, 朱述阳. 血清CEA CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响[J]. 河北医学, 2019, 25(11): 1761-1764.
LI Xueqin, ZHU Shuyang. Effects of Serum CEA CA125 and Cyfra21-1 Levels on the Prognosis of Patients with Advanced NSCLC. HeBei Med, 2019, 25(11): 1761-1764.
2019, Vol. 25 
冀公网安备13080202000677号